CAR T-Cell Therapy Outperformed Bispecific Antibodies
A meta-analysis revealed higher complete response rates in mantle cell lymphoma patients receiving CAR T-cell therapy.
Updated on Oct. 13, 2026 in Cancer
A meta-analysis comparing outcomes in relapsed mantle cell lymphoma patients found that CAR T-cell therapy achieved higher complete response rates than bispecific antibodies. The study, which concluded its literature search in October 2024, evaluated findings from 237 patients across five separate trials.
Why it matters
The analysis was conducted to address the current lack of head-to-head randomized trials for these two potent treatment options. By pooling existing data, researchers aim to better inform clinical decisions for patients who have exhausted at least two prior lines of therapy.
The meta-analysis pooled data from 237 patients with a median age range of 65 to 68.5 years. Patients receiving CAR T-cell therapy faced a 21% incidence rate of Grade 3 or higher neurotoxicity.
The players
Food and Drug Administration
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices.
The details
Researchers utilized random-effects models to compare the efficacy of therapies including mosunetuzumab, glofitamab, brexucabtagene autoleucel, and lisocabtagene maraleucel. This study focused specifically on patients who had previously undergone at least two lines of treatment for mantle cell lymphoma.
Timeline
The literature search for the meta-analysis concluded in October 2024.
The FDA granted traditional approval to brexucabtagene autoleucel on April 3, 2026.
The Big Picture
This meta-analysis offers a comparative evaluation of advanced immunotherapies, marking a shift toward synthesizing evidence in the absence of direct randomized trials for the FDA approval process for CAR T-cell therapies.
Patients with relapsed mantle cell lymphoma may discuss these findings with their oncologists to weigh the 70% complete response rate of CAR T-cell therapy against potential side effects like neurotoxicity. The results provide an additional evidence-based reference for those evaluating treatment options after at least two failed lines of therapy.
The takeaway
This study highlights the importance of analyzing existing trial data to clarify treatment outcomes for complex cancers. Future randomized trials will be necessary to confirm these observations and provide definitive guidance for clinical practice.
Further reading
For more information on current treatment standards, visit the Cancer section.
